Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27847582 | 0.86 | GAA (0.44) | EGLN2ATRRORCGRM5AAK1 | |
| SCHEMBL25226928 | 0.86 | ATR (0.44) | EGLN2ATRGSK3BDYRK1AAAK1 | |
| SCHEMBL29272503 | 0.82 | BRAF (0.44) | EGLN2ATRRIPK3GSK3BDYRK1A | |
| SCHEMBL25238596 | 0.82 | GABRA5 (0.45) | EGLN2ATRGSK3BDYRK1AAAK1 | |
| SCHEMBL828560 | 0.81 | TP53 (0.51) | — | |
| SCHEMBL19958489 | 0.81 | RORC (0.49) | RORCGRM5CYP3A4 | |
| SCHEMBL1192656 | 0.81 | ATR (0.50) | ATRGSK3BDYRK1AAAK1IRAK4 | |
| SCHEMBL30953487 | 0.81 | ATR (0.50) | ATRGSK3BDYRK1AAAK1IRAK4 | |
| SCHEMBL15057350 | 0.80 | EGLN2 (0.50) | EGLN2GSK3BDYRK1ACLK4 | |
| SCHEMBL1726534 | 0.80 | ABCB1 (0.45) | EGLN2RORCDYRK1AAAK1CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250165-B1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2018-07-25 | — | — | EP | disclosed |
| CN-103298788-A | Pyridine derivative and medicinal agent | NIPPON SHINYAKU CO LTD | 2013-09-11 | — | — | CN | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| EP-2250165-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | Merck Serono S.A. (CH) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009080663-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | EGLN2 2540/4885ATR 111/4885RIPK3 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.